SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantirs quarterly results beat expectations and lifted its outlook, with rapid U.S. commercial AI growth overtaking government revenue for the first time. The shares nevertheless fell, as traders debated whether strong growth was already priced in given the companys high valuation, while others viewed the selloff as a disconnect from the results.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apples earnings beat estimates, but traders focused on expected margin pressure from rising memory costs and weaker-than-expected China, iPad, and wearables results, driving a selloff despite strong iPhone sales. The community is split between viewing the drop as an overreaction to a solid quarter and seeing the outlook and valuation as reasons for caution.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavaxs Sanofi partnership is the main focus after a milestone was triggered by the start of a Phase 3 COVID-flu combination trial. Bulls view it as validation of the licensing model and a source of future royalties, while skeptics point to modest vaccine sales and question whether the Q3 results will show meaningful recurring revenue.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

CAPR is drawing attention ahead of the FDAs Nov. 22 decision on deramiocel for Duchenne muscular dystrophy, with traders focusing on the applications upper-limb function data and new commercial-hiring listings as possible signs of launch preparationnot confirmation of approval. Optimism about a limited upper-limb approval and potential short covering competes with concerns about the FDAs earlier advisory-panel vote and the risk of a rejection; some traders also cite INOs recent approval as a positive read-through, while leak claims remain speculation.

Upstart Holdings, Inc. engages in the provision of a cloud-based artificial intelligence lending platform. It operates through the following segments: Personal Lending, Auto Lending, and Other. The Personal Lending segment focuses on unsecured personal loans and small dollar loans. The Auto Lending segment is involved in auto refinance and auto retail loans. The Other segment refers to HELOCs and other. The company was founded by David Joseph Girouard, Anna Mongayt Counselman, and Paul Gu in December 2013 and is headquartered in San Mateo, CA.

Upstart Holdings Inc

Upstarts sharp selloff and repeated lows have traders focused on concerns about high interest rates, funding and debt, and the outlook for consumer lending ahead of earnings. Some expect further downside if results or guidance disappoint, while bullish traders argue the decline may be overdone and point to growth potential or a possible short squeeze.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracles planned stock-and-bond fundraising for its AI data-center buildout is drawing scrutiny over dilution, debt and the timing of the capital raise, alongside weakness in tech shares. Traders are split between viewing the drop as an overreaction to a previously disclosed plan and worrying that heavy AI spending may not deliver returns quickly enough.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

A report that nonprofit Usona may have submitted an FDA application for psilocybin in major depressive disorder has sparked fears that a competitor could reach the market before COMPASS Pathways COMP360 for treatment-resistant depression, pressuring its pricing and commercial opportunity. Traders debate whether Usonas MDD focus materially threatens COMPASSs TRD program, and some view the selloff as an overreaction; uncertainty over the report and COMPASSs own NDA timeline remains central.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvells agreed all-stock acquisition of Lumentum is driving attention, with traders focused on shareholder dilution, the long path to closing, and whether the deals price and execution risks outweigh its AI-optics rationale. The sharp selloff has fueled criticism that Marvell overpaid, while some investors argue the combination could strengthen its position in AI data-center connectivity over the long term.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Discussion centers on the U.S. midterm elections and how a possible shift in congressional control could affect DJT shares, with bearish traders anticipating pressure and bulls arguing the stock could rally. Many also characterize its moves as speculative pump-and-dump trading, while Iran-war and peace-talk headlines appear as a secondary source of market uncertainty.

iShares Trust - iShares Biotechnology ETF

iShares Biotechnology ETF

Biotechs pullback and relative resilience are the main focus: traders say IBB is holding up better than small-cap XBI, while debating whether recent sector strength and upcoming large-biotech earnings can sustain momentum.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Xeris Biopharma Welcomes Menassie M. Taddese to Board of Directors

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a leading endocrine and rare disease biopharmaceutical company committed to helping people realize better lives through the development and commercialization of innovative medicines, today announced the appointment of Menassie M. Taddese to its Board...

Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a leading, endocrine and rare disease biopharmaceutical company committed to helping people realize better lives through the development and commercialization of innovative medicines, today announced it will release its financial results and business...

Xeris Biopharma Reinforces Leadership in Endocrinology With Data Disclosures Spanning Commercial Portfolio and Pipeline at Multiple Scientific Meetings

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a leading, endocrine and rare disease biopharmaceutical company committed to helping people realize better lives through the development and commercialization of innovative medicines, today announced clinical and scientific data presentations from its...

Full Transcript: Xeris Biopharma Holdings Q2 2026 Earnings Call

Xeris Biopharma Holdings (NASDAQ:XERS) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below.
This content is powered by Benzinga APIs. For comprehensiveread more...

Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on October 1, 2026, the Compensation Committee of Xeris Board of...

Xeris Biopharma Reportedly Draws Takeover Interest — But Firm Says It’s ‘Not For Sale’

Equity

According to a Bloomberg report, Danish company Lundbeck has been working with advisers to explore a potential takeover of Xeris.

Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational, Once-Weekly Subcutaneous Levothyroxine for Hypothyroidism

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, will host an XP-8121 Program Overview today at 10 a.m. ET detailing a comprehensive...

Xeris Announces Details for XP-8121 Program Overview Webinar

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced details for a dedicated Program Overview webinar for XP-8121, the Companys...

Compared to Estimates, Xeris Biopharma (XERS) Q2 Earnings: A Look at Key Metrics

The headline numbers for Xeris Biopharma (XERS) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Xeris Biopharma Reports Second Quarter 2026 Financial Results

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced its financial results for the second quarter ended June 30, 2026. "The...

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Bearish Sentiment

<ul class="summary-bullets"><li>Xeris’s lead pipeline candidate for hypothyroidism could fetch between $1 billion and $3 billion annually.</li><li>Xeris focuses on endocrine and rare diseases and currently sells three treatments.</li><li>The company had $121.7 million in cash and cash equivalents as of the end of June.</li></ul>Xeris Biopharma (<a class="mention" data-mention="$XERS" data-symbol-id="XERS" href="https://stocktwits.com/symbol/XERS" target="_blank">XERS</a>) was in focus on Tuesday after Danish drugmaker Lundbeck reportedly expressed interest in acquiring the Chicago-based biotech firm focused on rare-disease treatments.According to a Bloomberg <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2026-09-29/lundbeck-is-said-to-express-interest-in-buying-xeris-biopharma">report</a> on Tuesday, Lundbeck has been working with advisers to explore a potential takeover, though there is no guarantee the interest will result in a deal.Xeris told Bloomberg that the company is “not for sale” and remains “laser focused” on developing and commercializing its medicines.<a href="https://stocktwits.com/symbol/XERS">XERS shares</a> surged more than 15% after the report was published but quickly pared the gains and turned negative. The stock is now trading around 2% lower.<h2 class="st-heading-2">A Look At Xeris’ Pipeline</h2>Xeris focuses on endocrine and rare diseases and currently sells three treatments, including Recorlev for Cushing’s syndrome, Gvoke for severe low blood sugar, and Keveyis for primary periodic paralysis, a rare disorder that causes episodes of muscle weakness or paralysis.Beyond its marketed products, Xeris’ pipeline is led by XP-8121, an experimental once-weekly injection for hypothyroidism.The company has announced plans to begin a Phase 3 study by year-end, with topline results expected in late 2028 and a potential U.S. launch in 2030. Xeris <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.xerispharma.com/news-releases/news-release-details/xeris-hosts-webinar-detailing-its-comprehensive-development">estimates</a> the treatment could eventually generate $1 billion to $3 billion in peak annual revenue.<h2 class="st-heading-2">Recorlev Drives Q2 Topline Growth</h2>The company posted a 29% jump in second-quarter (Q2) revenue to $92.1 million. Product revenue rose 34% to $91 million, driven largely by Recorlev, whose sales surged 81% to $56.8 million.Xeris reported a net loss of $31.1 million, or $0.18 per share, partly due to a $31 million non-cash charge related to a debt exchange. The company had $121.7 million in cash and cash equivalents as of the end of June.<h2 class="st-heading-2">Retail Turns ‘Extremely Bullish’ On <a class="mention" data-mention="$XERS" data-symbol-id="XERS" href="https://stocktwits.com/symbol/XERS" target="_blank">XERS</a></h2>Retail sentiment for <a class="mention" data-mention="$XERS" data-symbol-id="XERS" href="https://stocktwits.com/symbol/XERS" target="_blank">XERS</a> on Stocktwits turned ‘extremely bullish’ from ‘bullish’ over the past 24 hours, amid ‘extremely high’ message volumes. <a class="mention" data-mention="$XERS" data-symbol-id="XERS" href="https://stocktwits.com/symbol/XERS" target="_blank">XERS</a> was also among the top trending stocks on the platform.One user said, “Even if it’s not Lundbeck, we know the conversations are happening now.”<stembedurl>https://stocktwits.com/TymeTryethTroth/message/665351581</stembedurl>The stock has gained around 33% so far this year.Also read: <a href="https://stocktwits.com/news-articles/markets/equity/bofa-raises-immix-price-target-after-clinical-trial-result/cZMZ7RQRBWI">BofA Raises Odds Of Success For Immix Biopharma’s NXC-201 Therapy — Sees Over 190% Upside In IMMX Stock</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

SPDR S&P Biotech ETF

Up more than 3%

Flat to up 3%

Flat to down 3%

Down more than 3%

What’s your expected total return for the S&amp;P 500 ($SPY) in November?

Stocktwits

What’s your expected total return for the S&P 500 (

Current Price	$10.17
Prev Close	$10.71
Open	$10.71
Dividend Yield	0.00%
50-Day Moving Average	$9.34
Beta	1.06
Avg. Volume	2.3M
PE Ratio	-99.41

52-Week High	$11.42
52-Week Low	$5.25
Market Capitalization	$1.95B
EPS (Annual)	$0.0032
Price to Book	-181.38
Revenue Per Employee	$670,908.05

Feed

News

Sentiment

Earnings

Fundamentals

Info

XERS Fundamentals